title: Fortification of blood plasma from cancer patients with human serum albumin decreases the concentration of cisplatin-derived toxic hydrolysis products in vitro.
abstract: While cisplatin (CP) is still one of the world's bestselling anticancer drugs, its intravenous administration is inherently associated with severe, dose limiting toxic side-effects. Although the molecular basis of the latter are not well understood, biochemical transformations of CP in blood and the interaction of the generated platinum species with plasma proteins likely play a critical role since these processes will ultimately determine which platinum-species reach the intended tumor cells as well as non-target cells. Compared to healthy subjects, cancer patients often have decreased plasma human serum albumin (HSA) concentrations. Little, however, is known about how the plasma HSA concentration will affect the metabolism of CP. To gain insight, we obtained blood plasma from healthy adults (n = 20, 42 ± 4 g HSA per L) and pediatric cancer patients (n = 11, 26 ± 7 g HSA per L). After the incubation of plasma at 37 °C, a pharmacologically relevant dose of CP was added and the Pt-distribution therein was determined by size-exclusion chromatography coupled on-line to an inductively coupled plasma atomic emission spectrometer. At the 2 h time point, a 5.9% increase of toxic CP-derived hydrolysis products was detected in pediatric cancer patient plasma, while 9.8% less platinum was protein bound compared to plasma from healthy controls. These in vitro results suggest that the elevated concentration of highly reactive free CP-derived hydrolysis products in plasma may cause the toxic side-effects in cancer patients. More importantly, the deliberate increase of the plasma HSA concentration in cancer patients prior to CP treatment would represent a simple strategy to possibly alleviate the fraction of patients that suffer from drug induced toxic side-effects.
authors.affiliation: Department of Chemistry, University of Calgary, 2500 University Drive NW, Calgary, AB T2N 1N4, Canada. jgailer@ucalgary.ca.
authors.forename: Thomas T
authors.initials: TT
authors.lastname: Morris
authors.forename: Yibing
authors.initials: Y
authors.lastname: Ruan
authors.forename: Victor A
authors.initials: VA
authors.lastname: Lewis
authors.forename: Aru
authors.initials: A
authors.lastname: Narendran
authors.forename: Jürgen
authors.initials: J
authors.lastname: Gailer
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000097:blood / Q000378:metabolism / Q000627:therapeutic use* / Q000633:toxicity*; D002648:Child; D002945:Cisplatin / Q000097:blood / Q000378:metabolism / Q000627:therapeutic use* / Q000633:toxicity*; D064420:Drug-Related Side Effects and Adverse Reactions / Q000188:drug therapy / Q000517:prevention & control; D006801:Humans; D009369:Neoplasms / Q000097:blood / Q000188:drug therapy / Q000378:metabolism; D012709:Serum Albumin / Q000378:metabolism* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D012709:Serum Albumin; D002945:Cisplatin